Shots:

• CytoDyn to receive quarterly payments based on the profit-sharing arrangement and will supply Leronlimab to American Regent. American Regent will be responsible for the distribution of Leronlimab post completion of CytoDyn’s ongoing clinical trials including the FDA’s approval in the US
• CytoDyn’s P-IIb/III trial is enrolling patients which will be evaluating leronlimab vs PBO (N=75) in 390 severe and critically ill COVID-19 patients in the ratio (2:1) and has already enrolled for P-II trial. The US FDA has also granted 60 eIND with expected clinical updates in the coming weeks
• Leronlimab (PRO 140) IgG4 mAb that blocks CCR5 receptor and has received the US FDA’s Fast track Designation in combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. The product has also completed nine clinical trials in over 800 people and met 1Eps in P-III in HIV-infected treatment-experienced patients

Click here to read full press release/ article | Ref: CytoDyn | Image: Behance